Suchergebnisse - "Usmani, Saad Z"

PubPharm (21)

1

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

2

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

3

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

4

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

enthalten in: Blood cancer journal | 2023

von Tan, C. | Derkach, A. | Nemirovsky, D. | +18

UpdateOf: Res Sq. 2023 Feb 24;:. - PMID 36865246

5

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma : Findings from the MASTER and GRIFFIN Trials

enthalten in: Transplantation and cellular therapy | 2023

von Chhabra, S. | Callander, N. | Watts, N. | +34

6

Cross Fire : Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma

enthalten in: Hematology/oncology and stem cell therapy | 2023

von Korde, N. | Usmani, S.

7

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

enthalten in: Blood cancer journal | 2023

von Shah, U. | Whiting, K. | Devlin, S. | +16

8

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

enthalten in: The oncologist | 2022

von Jakubowiak, A. | Kumar, S. | Medhekar, R. | +10

9

Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

enthalten in: Bone marrow transplantation | 2022

von Pasvolsky, O. | Yeshurun, M. | Fraser, R. | +27

10

Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British journal of haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35